Protagonist Therapeutics (PTGX) News Today $45.91 +0.09 (+0.20%) Closing price 04:00 PM EasternExtended Trading$44.57 -1.34 (-2.92%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from AnalystsProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has earned a consensus recommendation of "Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and oneMay 22 at 3:07 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a report on Monday.May 21 at 8:15 AM | marketbeat.comSoleus Capital Management L.P. Makes New $10.62 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Soleus Capital Management L.P. purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 275,000 shares of the company's stocMay 21 at 8:13 AM | marketbeat.comDeutsche Bank AG Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Deutsche Bank AG lifted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 14.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 137,932 shares of the company's stock after acquiring an additional 17,763 shares during the perMay 21 at 3:52 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Earns "Buy" Rating from HC WainwrightMay 21 at 2:03 AM | americanbankingnews.comRTW Investments LP Has $212.24 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)RTW Investments LP raised its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,498,545 shares of the company's stock after purchasing an additMay 18, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Northern Trust CorpNorthern Trust Corp grew its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 8.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 628,580 shares of the company's stMay 15, 2025 | marketbeat.comJefferies Financial Group Inc. Has $57.50 Million Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Jefferies Financial Group Inc. trimmed its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 17.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,489,495 shares of the compaMay 13, 2025 | marketbeat.comCrestline Management LP Invests $489,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Crestline Management LP bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 12,681 shares of the company's stock, valued at approximately $489,000. SeveralMay 13, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Algert Global LLCAlgert Global LLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 17,720 shares of the company's stock after selling 97,959 shares during theMay 13, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for PTGXProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2025 EPS estimates for Protagonist Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings ofMay 13, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for PTGX Q2 Earnings?May 13, 2025 | americanbankingnews.comDriehaus Capital Management LLC Sells 105,654 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Driehaus Capital Management LLC lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 23.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 339,698 shares of the company's stockMay 12, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for PTGX EarningsProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Wedbush increased their Q2 2025 earnings per share estimates for shares of Protagonist Therapeutics in a note issued to investors on Wednesday, May 7th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($0.59) per shaMay 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Farallon Capital Management LLCFarallon Capital Management LLC boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,930,006 shares of the company's stock after buying an additional 6May 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by AQR Capital Management LLCAQR Capital Management LLC increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 9.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 150,097 shares of the company's stocMay 11, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Purchases 8,576 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)The Manufacturers Life Insurance Company lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 7.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 124,341 shares of the company's stock after puMay 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comDeep Track Capital LP Invests $38.60 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Deep Track Capital LP purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,000,000 shares of the company's stock, valued atMay 9, 2025 | marketbeat.comProtagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?May 8, 2025 | finance.yahoo.comBraidwell LP Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Braidwell LP bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,109 shares of the company's stock, valued at approximately $776May 8, 2025 | marketbeat.comBellevue Group AG Purchases 11,372 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Bellevue Group AG increased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 92.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,718 shares of the company's stock after acqMay 7, 2025 | marketbeat.comFreestone Grove Partners LP Buys New Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Freestone Grove Partners LP purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 6,644 sharMay 7, 2025 | marketbeat.comProtagonist Therapeutics: Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | finanznachrichten.deProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Increased by BVF Inc. ILBVF Inc. IL lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,900,015 shares of the company's stock after purchasing anMay 6, 2025 | marketbeat.comVoya Investment Management LLC Sells 31,225 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Voya Investment Management LLC trimmed its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 27.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 82,627 shares of theMay 5, 2025 | marketbeat.comTower Research Capital LLC TRC Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Tower Research Capital LLC TRC raised its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1,946.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,369 shares of the company's stock after buying an additionMay 5, 2025 | marketbeat.com683 Capital Management LLC Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)683 Capital Management LLC decreased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 410,00May 4, 2025 | marketbeat.comMarshall Wace LLP Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Marshall Wace LLP trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 93.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the company's stMay 4, 2025 | marketbeat.comProtagonist Therapeutics Inc PTGXMay 3, 2025 | morningstar.comTwo Sigma Securities LLC Invests $212,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Two Sigma Securities LLC acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,505 shares of theMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Boothbay Fund Management LLC purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 20,188 shares of the compMay 2, 2025 | marketbeat.comProtagonist Therapeutics (PTGX) Projected to Post Earnings on TuesdayProtagonist Therapeutics (NASDAQ:PTGX) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-protagonist-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Raised by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD raised its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 6.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,392,652 shares of the company's stock after purchasing an additional 83,185 shares during theMay 1, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Artia Global Partners LPArtia Global Partners LP increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 136.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 293,851 shares of theApril 29, 2025 | marketbeat.comWells Fargo & Company MN Raises Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Wells Fargo & Company MN raised its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 32.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,796 shares of the company's stock afApril 29, 2025 | marketbeat.comXTX Topco Ltd Trims Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)XTX Topco Ltd lowered its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 54.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 6,744 shares of the company's stock after selling 8,057 shares during the quarter. XTX TopcoApril 28, 2025 | marketbeat.comGuggenheim Capital LLC Has $736,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Guggenheim Capital LLC grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 141.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,078 shares of the company's stockApril 27, 2025 | marketbeat.comEversept Partners LP Has $26.20 Million Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Eversept Partners LP boosted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 52.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 678,787 shares of the company's stock after purchasiApril 24, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,756 SharesApril 24, 2025 | insidertrades.comPeak6 LLC Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Peak6 LLC purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 9,000 shares of the company's stock, valued at approximately $347,000. A number of other hedge funds have alsApril 24, 2025 | marketbeat.comProtagonist Therapeutics Stock Short Interest Report | NASDAQ:PTGX | BenzingaApril 20, 2025 | benzinga.comRenaissance Technologies LLC Buys 77,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Renaissance Technologies LLC raised its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 53.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 221,167 shares of the companyApril 20, 2025 | marketbeat.comInvesco Ltd. Acquires 85,800 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Invesco Ltd. increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 13.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 738,952 shares of the company's stockApril 20, 2025 | marketbeat.comCapital Fund Management S.A. Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Capital Fund Management S.A. acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,058 shares of the company's stocApril 18, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Up 6.1% - Should You Buy?Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 6.1% - Here's WhyApril 17, 2025 | marketbeat.comAffinity Asset Advisors LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Affinity Asset Advisors LLC acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 130,000 shares of the company's stock, valued at approximately $5,April 17, 2025 | marketbeat.comAlliancebernstein L.P. Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Alliancebernstein L.P. lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 16.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,225 shares of the company'sApril 17, 2025 | marketbeat.comFranklin Resources Inc. Purchases 7,279 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Franklin Resources Inc. boosted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 8.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 88,870 shares of the company's stock after acquApril 14, 2025 | marketbeat.comAviva PLC Invests $565,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Aviva PLC bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 14,627 shares of the company's stock, valued at approApril 13, 2025 | marketbeat.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼1.180.69▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼76▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viatris News Moderna News Ascendis Pharma A/S News Qiagen News Roivant Sciences News Revolution Medicines News Elanco Animal Health News Blueprint Medicines News BridgeBio Pharma News Verona Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTGX Stock Free PTGX Stock Alerts